Video: Clinical Update on the Emerging Threat of Nontuberculous Mycobacterial Lung Disease
  • CME

In this interactive, CME-certified video, gain expert insights on diagnosing and managing patients with nontuberculous mycobacterial lung disease.
Stephen Ruoss, MD
Kevin L. Winthrop, MD, MPH ID
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: February 14, 2020 Expiration: February 13, 2021
Multimedia Video: Clinical Update on the Emerging Threat of Nontuberculous Mycobacterial Lung Disease
This program is divided into short segments. After reviewing all segments, click the Claim Credit button to complete the CME/CE posttest and evaluation.
Overview (10 minutes)
Clinical overview of nontuberculous mycobacterial lung disease, including epidemiology and risk factors
Launch Overview (10 minutes)
Diagnosis (16 minutes)
Gain expert guidance on diagnosing nontuberculous mycobacterial lung diseases, including recommended workup and species determination
Launch Diagnosis (16 minutes)
First-line Treatment (15 minutes)
Experts discuss current best practices for first-line treatment of nontuberculous mycobacterial lung diseases
Launch First-line Treatment (15 minutes)
Defining Treatment Outcomes (10 minutes)
Expert perspectives on defining treatment outcomes in patients receiving therapy for nontuberculous mycobacterial lung diseases
Launch Defining Treatment Outcomes (10 minutes)
Treatment-Refractory NTM-LD (14 minutes)
Watch experts discuss how they manage patients with refractory/relapsing nontuberculous mycobacterial lung diseases
Launch Treatment-Refractory NTM-LD (14 minutes)
Conclusions (2 minutes)
Summary of take-home messages from this expert discussion
Launch Conclusions (2 minutes)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the clinical, radiographic, and microbiologic criteria for making an NTM-LD diagnosis
  • Compare and contrast current and emerging antimicrobial therapies for treatment-refractory NTM-LD regarding efficacy, safety, and adherence considerations

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
American Thoracic Society Logo
Supported by an educational grant from
Insmed

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Stephen Ruoss, MD

Professor of Medicine
Pulmonary and Clinical Care
Stanford University Medical Center
Stanford, California

Stephen Ruoss, MD, has disclosed that he has received honoraria from Insmed.
Kevin L. Winthrop, MD, MPH ID

Professor of Public Health
Professor of Infectious Diseases and Ophthalmology

OHSU-PSU School of Public Health
Oregon Health & Science University
Portland, Oregon

Kevin L. Winthrop, MD, MPH ID, has disclosed that he has received funds for research support from Insmed and consulting fees from Horizon, Insmed, Johnson & Johnson, Paratek, and RedHill.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Sharon Hwang, MD, MPH

Editorial Contributor

Sharon Hwang, MD, MPH, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for pulmonologists, infectious disease specialists, and other healthcare providers who care for patients with NTM-LD.

Goal

The goal of this activity is to improve participants’ competence in applying current and emerging strategies in the diagnosis and treatment of patients with nontuberculous mycobacterial lung disease.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 14, 2020, through February 13, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentary on prevention and emerging treatment strategies for the COVID-19 pandemic from CCO

Daniel R. Kuritzkes, MD Released: March 19, 2020

Celine Gounder, MD, ScM, FIDSA: how healthcare providers can be prepared for when coronavirus comes to them. Testing for COVID-19, symptoms, screening, from CCO

Celine Gounder, MD, ScM, FIDSA Released: March 13, 2020

Stephen Ruoss, MD, and Kevin Winthrop, MD, MPH ID: Slides on best practice for diagnosis and management of nontuberculous mycobacterial lung disease

Stephen Ruoss, MD Kevin L. Winthrop, MD, MPH ID Released: February 14, 2020

Downloadable slides with guidance on treatment of invasive fungal infections such as candidiasis, aspergillosis, and mucormycosis in high-risk patients

Thomas F. Patterson, MD, FACP, FIDSA
Program Director
James Lewis, PharmD, FIDSA
Released: April 24, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?